INT99615

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2001
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 12
Total Number 14
Disease Relevance 2.98
Pain Relevance 0.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (GP1BA) plasma membrane (GP1BA)
Anatomy Link Frequency
platelets 7
GP1BA (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 6 91.60 High High
agonist 37 90.24 High High
Angina 8 87.96 High High
anesthesia 5 75.00 Quite High
aspirin 5 50.00 Quite Low
methadone 3 50.00 Quite Low
Restless leg syndrome 2 50.00 Quite Low
Inflammation 12 5.00 Very Low Very Low Very Low
cytokine 8 5.00 Very Low Very Low Very Low
withdrawal 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hemorrhage 3 99.12 Very High Very High Very High
Cataract 1 96.36 Very High Very High Very High
Heart Rate Under Development 20 95.80 Very High Very High Very High
Sensorineural Hearing Loss 1 94.88 High High
Peripheral Arterial Disease 3 94.32 High High
Alport Syndrome 1 93.76 High High
Atherosclerosis 4 93.60 High High
Bronchitis 42 91.96 High High
Headache 6 91.60 High High
Vomiting 4 90.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The tendency to bleeding is highly variable and is due to decreased expression of the GP1b-V-IX complex on the surface of platelets, leading to altered platelet-vessel wall and platelet-platelet interactions.
Gene_expression (expression) of GP1b in platelet associated with hemorrhage
1) Confidence 0.75 Published 2003 Journal Rev Esp Anestesiol Reanim Section Abstract Doc Link 14552110 Disease Relevance 0.99 Pain Relevance 0.07
The concentration of platelets GPII b/IIIa and GP Ib/IX was estimated by ELISA method using monoclonal antibody against GPII b/IIIa (CD41a) and GPI b/IX (CD42a Immunotech).
Gene_expression (concentration) of GP Ib in platelets
2) Confidence 0.65 Published 2003 Journal Int Angiol Section Body Doc Link 12865882 Disease Relevance 0.28 Pain Relevance 0
100, to detect the activated GPIIb/IIIa receptor, Becton Dickinson, San Jose, CA), mouse anti-human CD42b:RPE-Cy5 and mouse anti-human CD38:RPE (1?
Gene_expression (human) of CD42b
3) Confidence 0.65 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2735777 Disease Relevance 0.16 Pain Relevance 0
100, BD Biosciences) [18], mouse anti-human tissue factor CD142:RPE and mouse anti-human CD42b:FITC or mouse anti-human CD38:FITC, alternatively mouse anti-human CD66:FITC, simultaneously or isotype controls IgG1:FITC and IgG1:PE (all from BD Biosciences).


Gene_expression (anti) of CD42b
4) Confidence 0.65 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2735777 Disease Relevance 0.07 Pain Relevance 0.05
10, Dako), mouse anti-human CD42b:RPE-Cy5 and mouse anti-human CD38:RPE or mouse anti-human CD66:RPE.
Gene_expression (anti) of CD42b
5) Confidence 0.65 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2735777 Disease Relevance 0.17 Pain Relevance 0.03
Similarly, platelet-neutrophil aggregates were detected by simultaneous incubation with mouse anti-human CD42b:RPE-Cy5 and mouse IgM anti-human CD66:FITC (1?
Gene_expression (anti) of CD42b in platelet
6) Confidence 0.65 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2735777 Disease Relevance 0.05 Pain Relevance 0
RESULTS: AA, ADP, and TRAP-6 markedly increased the expression of CD62P on platelets, whereas CD42b (shedding) and PAC-1 (heterotypic conjugates) expression decreased.
Gene_expression (expression) of CD42b in platelets
7) Confidence 0.57 Published 2008 Journal Anesth. Analg. Section Body Doc Link 18499605 Disease Relevance 0 Pain Relevance 0
The expression of platelet receptors was determined by using the following monoclonal antibodies: CD31 (PECAM-1), CD41 (GPIIb), CD42b (GPIb), CD51/CD61 (vitronectin receptor), CD62p (P-selectin), CD63 (LIMP or LAMP-3), CD107a (LAMP-1), CD151 (PETA-3), and PAC-1 for fibrinogen-platelet binding determination (PharMingen, San Diego, CA).
Spec (determined) Gene_expression (expression) of GPIb in platelet
8) Confidence 0.34 Published 2001 Journal Thromb. Res. Section Body Doc Link 11728532 Disease Relevance 0.09 Pain Relevance 0
However, CD42b, CD41/61 and CD62p expression returned to the pre-operative level in group V.
Gene_expression (expression) of CD42b
9) Confidence 0.27 Published 2006 Journal Acta Anaesthesiol Scand Section Body Doc Link 16987338 Disease Relevance 0 Pain Relevance 0
At 6 h after intravenous infusion, the trend of decreasing expression of activated CD42b, CD41/61 and CD62p was maintained in group H.
Gene_expression (expression) of CD42b
10) Confidence 0.27 Published 2006 Journal Acta Anaesthesiol Scand Section Body Doc Link 16987338 Disease Relevance 0 Pain Relevance 0
The expression of CD42b, CD41/61 and CD62p in vivo was assessed on non-stimulated platelets and adenosine diphosphate (ADP) agonist-activated platelets using flow cytometry.
Gene_expression (expression) of CD42b in platelets
11) Confidence 0.27 Published 2006 Journal Acta Anaesthesiol Scand Section Body Doc Link 16987338 Disease Relevance 0 Pain Relevance 0
HES200/0.5 and HES130/0.4 reduced the CD42b, CD41/61 and CD62p expression of ADP-agonist-activated platelets at 15 min after intravenous infusion.
Gene_expression (expression) of CD42b in platelets
12) Confidence 0.27 Published 2006 Journal Acta Anaesthesiol Scand Section Body Doc Link 16987338 Disease Relevance 0 Pain Relevance 0
Secondary efficacy variables were: treatment response according to three criteria (BSS total score of <3 on day 7, decrease in BSS total score of at least 7 points from day 0 to day 7 and BSS total score <3 on day 7 combined with a decrease in BSS total score of at least 7 points from day 0 to day 7), onset of effect, change in the total score of individual symptoms and, change of general symptoms (e.g.
Gene_expression (change) of BSS total score
13) Confidence 0.07 Published 2010 Journal Acta Paediatrica (Oslo, Norway : 1992) Section Body Doc Link PMC2855831 Disease Relevance 0.58 Pain Relevance 0.18
Secondary efficacy variables were: treatment response according to three criteria (BSS total score of <3 on day 7, decrease in BSS total score of at least 7 points from day 0 to day 7 and BSS total score <3 on day 7 combined with a decrease in BSS total score of at least 7 points from day 0 to day 7), onset of effect, change in the total score of individual symptoms and, change of general symptoms (e.g.
Gene_expression (change) of BSS total score
14) Confidence 0.07 Published 2010 Journal Acta Paediatrica (Oslo, Norway : 1992) Section Body Doc Link PMC2855831 Disease Relevance 0.60 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox